HTGM - HTG Molecular completes product design lock for planned transcriptome panel

HTG Molecular Diagnostics (HTGM) has completed product design lock for the HTG Transcriptome Panel and announced three Early Adopter Program ((EAP)) collaborators.Shares up more than 8% premarket.The panel, expected to be called the HTG Transcriptome Panel, will measure about 20K mRNA targets, with a planned research use only commercial launch in the third quarter of 2021.Achieving design lock allows HTG to formally begin its previously announced EAP with several collaborators with whom HTG has been planning studies with for the past several months, the company said.The company has signed EAP collaboration agreements with three top institutions in the US, including the University of Texas MD Anderson Cancer Center, Duke University Medical Center and Saint John’s Cancer Institute.The EAP will also provide collaborators with priority access to product purchases and the ability to contract with HTG to execute laboratory service projects on their behalf prior to commercial launch.

For further details see:

HTG Molecular completes product design lock for planned transcriptome panel